Transcript Cherise Scott`s presentation

Market understanding:
new data on the
purchasing habits of 22
high-burden countries
Cherise Scott
Director, Pediatric Programs
[email protected]
October 31, 2014
Satellite Symposium: The pediatric TB drug market:
progress and future direction
Overview
Speeding Treatments to End Pediatric TB (STEP)-TB
Unmet Medical Need
Not enough kids being treated – and not being
treated appropriately
Goal
Increase access to correctly dosed, properly
formulated, affordable, high quality pediatric
TB medicines
Implementing Partner
Timeline
High quality, child-friendly, properly dosed
HRZ, HR and E products available by early 2016
2
Three Key Outcomes
Scope of Pediatric Initiative
Market Catalyzed
• Market Research--How
many patients? Where?
How are they currently
being treated?
• Manufacturers’
commitments
• Momentum and
visibility
Drugs Available
• Correct dosage &
dispersible form for
HRZ, HR, and E
• Shorten gap between
approval of adult
products vs. pediatric
products
Uptake Influenced
• Global treatment
guidelines adopted
• National guidelines
developed and health
workers trained
• Child TB included in
NSPs and Global Fund
Concept Notes
• Funding committed for
product and
implementation
Mid- 2013
Mid- 2016
3
Purpose of Procurement Study
What we learn from the purchasing practices of countries?
• To understand countries readiness to adopt new child-friendly
formulations
• To understand procurement processes and timelines in priority
countries including key drivers and criteria for decision-making
• To obtain insight into the types and sources of funding used for
pediatric treatments
• To identify potential barriers and bottlenecks to introduction and
scale up of new formulations
• To gather data in order to inform targeted uptake planning
activities and specific country strategies
• To landscape important stakeholders and partners in priority
countries
4
Initial Analysis
• Considered the largest supplier to national TB programs of quality
pediatric TB drugs
• Possesses the most comprehensive data set on pediatric TB drug
procurement
• Supplies products to countries through a direct procurement
service and also offers grants to countries through donor funds
• 12 HBCs procure pediatric products from GDF as of 2014
• Pediatrics products procured by grants and direct purchase using
donor funds
5
Current Pediatric TB Market Understanding
Source:
2014 WHO Global TB Report
GDF Procurement Database
6
Market Quantification
172,740
Modeling the pediatric TB Burden in 22 HBCs
MEDIAN PEDIATRIC TB NEW CASES PER YEAR IN 22 HBCS
3,475
3,596
4,225
6,773
8,153
8,292
8,638
9,154
9,156
12,134
13,684
13,916
25,761
28,090
29,802
31,028
35,092
35,328
35,556
35,645
47,691
 Current
Global Drug
Facility (GDF)
Clients
7
HBCs supplied Peds Rx by the GDF
What we know
• Evidence that procured based on 2010 Rapid Advice
Afghanistan
Bangladesh
Cambodia
Kenya
Myanmar
Nigeria
Pakistan
• Policy and Implementation of the 2010 Rapid Advice
Afghanistan
Bangladesh
Cambodia
Congo (DR)
Kenya
Mozambique
Myanmar
Nigeria
Pakistan
Tanzania (UR)
Uganda
Viet Nam
8
HBCs NOT supplied Peds Rx by the GDF
What we know
Brazil
China
Ethiopia
India
Indonesia
Policy change and adoption to 2010 Rapid Advice;
procure from PAHO
Policy unknown; NTP has shown interest; Adult
products used for children
Policy change and adoption of 2010 Rapid Advice;
procurement unknown
Modified policy; some indication that changing to daily
dosing; extent of use of pediatric FDCs unclear
Policy change and adoption of 2010 Rapid Advice; local
procurement of pediatric FDCs (NOT PQ’d)
9
HBCs NOT supplied Peds Rx by the GDF
What we know
Philippines
Policy change and adoption of 2010 Rapid Advice; local
procurement; adult products and syrups are used
Russian Federation
Policy unknown; adult products used
South Africa
Thailand
Zimbabwe
Policy change and adoption of 2010 Rapid Advice; local
procurement
Policy change and incomplete implementation of 2010
Rapid Advice; create on solutions using adult products
from local manufacturers
Policy change and adoption of 2010 Rapid Advice;
unknown procurement
10
Conclusions/Next Steps
Using the data to inform product introduction and uptake
• Underscores the need for strategy to access the markets outside of
the GDF to create a viable market
• Feeds into larger efforts to understand all the aspects of the market
especially in specific countries
• Procurement within the private sector needs to be further
ascertained in these markets
• Country adoption of formulations can not be taken for granted
• Understanding where, when and what regarding country
procurement of products to treat children shows where to target
product launch/introduction efforts
• The timeline and location can be charted for introduction of the
new pediatric formulations
11
Thank you!
For more information on
childhood TB go to:
tballiance.org/children
12